文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危/局部晚期前列腺癌IMRT联合盆腔淋巴结照射的患者报告毒性:全国人群研究

Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-07-24

该研究基于英国国家医疗服务体系2014年4月至2016年9月诊断的高危或局部晚期前列腺癌IMRT患者,问卷随访至少18个月,比较前列腺仅照射(PO-IMRT)与前列腺+盆腔淋巴结照射(PPLN-IMRT)的患者报告结局。5468例应答者中4196例(76.7%)接受PO-IMRT、1272例(23.3%)接受PPLN-IMRT;结论认为额外盆腔淋巴结照射未导致临床有意义的毒性增加。

核心结论

  • 额外盆腔淋巴结照射未导致前列腺癌IMRT患者报告的功能结局和健康相关生活质量出现临床有意义的毒性增加。

研究设计与样本

  • 基于英国国家医疗服务体系2014年4月至2016年9月诊断的高危或局部晚期前列腺癌IMRT患者的全国人群研究。
  • 诊断后至少18个月邮寄问卷,收集EPIC-26和EQ-5D-5L患者报告结局,采用线性回归比较PPLN-IMRT与PO-IMRT并调整患者、肿瘤和治疗特征。

主要发现

  • 7017例收到问卷,5468例(77.9%)应答;4196例(76.7%)接受PO-IMRT,1272例(23.3%)接受PPLN-IMRT。

关键数值与推荐

  • EPIC-26功能领域评分范围0-100,分数越高表示结局越好。

临床怎么用

  • 对于高危或局部晚期前列腺癌患者,IMRT基础上增加盆腔淋巴结照射未显示临床有意义的患者报告毒性增加,支持在需要时考虑该治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Little is known about the toxicity of additional pelvic lymph node irradiation in men receiving intensity modulated radiation therapy (IMRT) for prostate cancer. The aim of this study was to compare patient-reported outcomes after IMRT to the prostate only (PO-IMRT) versus the prostate and pelvic lymph nodes (PPLN-IMRT). METHODS AND MATERIALS: Patients who received a diagnosis of high-risk or locally advanced prostate cancer in the English National Health Service between April 2014 and September 2016 who were treated with IMRT were mailed a questionnaire at least 18 months after diagnosis. Patient-reported urinary, sexual, bowel, and hormonal functional domains on a scale from 0 to 100, with higher scores indicating better outcomes, and generic health-related quality of life were collected using the Expanded Prostate Cancer Index Composite 26-item version and EQ-5D-5L. We used linear regression to compare PPLN-IMRT versus PO-IMRT with adjustment for patient, tumor, and treatment characteristics. RESULTS: Of the 7017 men who received a questionnaire, 5468 (77.9%) responded; 4196 (76.7%) had received PO-IMRT and 1272 (23.3%) PPLN-IMRT. Adjusted differences in the Expanded Prostate Cancer Index Composite 26-item version domain scores were smaller than 1 (P always >.2), except for sexual function, with men who had PPNL-IMRT reporting a lower mean score (adjusted difference, 2.3; 95% confidence interval, 0.9-3.7; P = .002). This did not represent a clinically relevant difference. There was no significant difference in health-related quality of life (P = .5). CONCLUSIONS: Additional pelvic lymph node irradiation does not lead to clinically meaningful increases in the toxicity of IMRT for prostate cancer according to patient-reported functional outcomes and health-related quality of life.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Parry MG, Nossiter J, Cowling TE, et al. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2020. PMID: 32717261. doi:10.1016/j.ijrobp.2020.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。